Related references
Note: Only part of the references are listed.Understanding the Cardiovascular Effects of Incretin
Ji Sung Yoon et al.
DIABETES & METABOLISM JOURNAL (2011)
Visfatin: a new player in mesangial cell physiology and diabetic nephropathy
Hye Kyoung Song et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasmogen activator inhibitor-1 expression
Hongbin Liu et al.
JOURNAL OF ENDOCRINOLOGY (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry
Alfredo E. Rodriguez et al.
EUROPEAN HEART JOURNAL (2007)
Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1
Kei Ohnuma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
S Ristic et al.
DIABETES OBESITY & METABOLISM (2005)
Caspases: pharmacological manipulation of cell death
IN Lavrik et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
A Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
T Nyström et al.
REGULATORY PEPTIDES (2005)
Adiponectin and future coronary heart disease events among men with type 2 diabetes
MB Schulze et al.
DIABETES (2005)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Plasma adiponectin levels and risk of myocardial infarction in men
T Pischon et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model
Y Yu et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
T Nyström et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
J Buteau et al.
DIABETOLOGIA (2004)
Enhancing incretin action for the treatment of type 2 diabetes
DJ Drucker
DIABETES CARE (2003)
Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease
N Marx et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor
J Buteau et al.
DIABETES (2003)
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
DJ Drucker
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2003)
Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits
E Mori et al.
CIRCULATION (2002)
Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys
K Egashira et al.
CIRCULATION RESEARCH (2002)
Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with Type 1 diabetes
PR Maxwell et al.
DIABETIC MEDICINE (2001)
Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes
MGV Petroff et al.
CIRCULATION RESEARCH (2001)
Mechanisms of diabetic vasculopathy: An overview
ME Cooper et al.
AMERICAN JOURNAL OF HYPERTENSION (2001)
Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries
FGP Welt et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy
FL Li-Saw-Hee et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2000)
The mechanisms of coronary restenosis: insights from experimental models
GAA Ferns et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2000)
Share Paper
